Latest News:

Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®

Pharmaterials rebrands to Quotient Sciences

5th April 2018

Nottingham, U.K., Apr. 05, 2018 — Quotient Sciences (“Quotient”), the drug development services organization, announces that it has completed the integration and rebrand of Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.


Pharmaterials, now named Quotient Sciences (Reading) Limited, will play a key role in expanding and strengthening Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing, and support the continued growth of Quotient’s Translational Pharmaceutics® platform.


The Reading business has a strong reputation in the development of small molecule drug products for oral and inhaled delivery and bolsters Quotient’s formulation development and manufacturing services. The 48,000 sq ft. facility includes an additional 13 GMP manufacturing suites, high potency containment capabilities and expertise across all key solubilisation technologies including spray drying, hot melt extrusion, lipidic systems and micronization.


Quotient Sciences continues to focus on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.

View this press release here.

For further information, please contact:
Quotient Sciences
Robin Bodicoat
Marketing Director
Tel: +44 (0)115 931 5102
Email: robin.bodicoat@quotientsciences.com

News

Read related news

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.